Literature DB >> 35430567

Effects of GSK-J4 on JMJD3 Histone Demethylase in Mouse Prostate Cancer Xenografts.

Anna Sanchez1,2, Frédérique Penault-Llorca2,3, Yves-Jean Bignon1,2, Laurent Guy2,4, Dominique Bernard-Gallon5,2.   

Abstract

BACKGROUND/AIM: Histone methylation status is required to control gene expression. H3K27me3 is an epigenetic tri-methylation modification to histone H3 controlled by the demethylase JMJD3. JMJD3 is dysregulated in a wide range of cancers and has been shown to control the expression of a specific growth-modulatory gene signature, making it an interesting candidate to better understand prostate tumor progression in vivo. This study aimed to identify the impact of JMJD3 inhibition by its inhibitor, GSK4, on prostate tumor growth in vivo.
MATERIALS AND METHODS: Prostate cancer cell lines were implanted into Balb/c nude male mice. The effects of the selective JMJD3 inhibitor GSK-J4 on tumor growth were analyzed by bioluminescence assays and H3K27me3-regulated changes in gene expression were analyzed by ChIP-qPCR and RT-qPCR.
RESULTS: JMJD3 inhibition contributed to an increase in tumor growth in androgen-independent (AR-) xenografts and a decrease in androgen-dependent (AR+). GSK-J4 treatment modulated H3K27me3 enrichment on the gene panel in DU-145-luc xenografts while it had little effect on PC3-luc and no effect on LNCaP-luc. Effects of JMJD3 inhibition affected the panel gene expression.
CONCLUSION: JMJD3 has a differential effect in prostate tumor progression according to AR status. Our results suggest that JMJD3 is able to play a role independently of its demethylase function in androgen-independent prostate cancer. The effects of GSK-J4 on AR+ prostate xenografts led to a decrease in tumor growth. Copyright
© 2022, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  AR status; GSK-J4; H3K27me3; JMJD3; Prostate cancer; epidrugs; epigenetics; xenografts

Mesh:

Substances:

Year:  2022        PMID: 35430567      PMCID: PMC9016480          DOI: 10.21873/cgp.20324

Source DB:  PubMed          Journal:  Cancer Genomics Proteomics        ISSN: 1109-6535            Impact factor:   4.069


  56 in total

Review 1.  Targeting EZH2 in cancer therapy.

Authors:  Makoto Yamagishi; Kaoru Uchimaru
Journal:  Curr Opin Oncol       Date:  2017-09       Impact factor: 3.645

2.  The Inhibition of the Histone Methyltransferase EZH2 by DZNEP or SiRNA Demonstrates Its Involvement in MGMT, TRA2A, RPS6KA2, and U2AF1 Gene Regulation in Prostate Cancer.

Authors:  Driss El Ouardi; Mouhamed Idrissou; Anna Sanchez; Frédérique Penault-Llorca; Yves-Jean Bignon; Laurent Guy; Dominique Bernard-Gallon
Journal:  OMICS       Date:  2019-12-31

3.  Vitamin C-dependent lysine demethylase 6 (KDM6)-mediated demethylation promotes a chromatin state that supports the endothelial-to-hematopoietic transition.

Authors:  Tian Zhang; Ke Huang; Yanling Zhu; Tianyu Wang; Yongli Shan; Bing Long; Yuhang Li; Qianyu Chen; Pengtao Wang; Shaoyang Zhao; Dongwei Li; Chuman Wu; Baoqiang Kang; Jiaming Gu; Yuchan Mai; Qing Wang; Jinbing Li; Yanqi Zhang; Zechuan Liang; Lin Guo; Fang Wu; Shuquan Su; Junwei Wang; Minghui Gao; Xiaofen Zhong; Baojian Liao; Jiekai Chen; Xiao Zhang; Xiaodong Shu; Duanqing Pei; Jinfu Nie; Guangjin Pan
Journal:  J Biol Chem       Date:  2019-07-24       Impact factor: 5.157

4.  Increased expression of hypoxia inducible factor-1alpha in rat and human prostate cancer.

Authors:  H Zhong; F Agani; A A Baccala; E Laughner; N Rioseco-Camacho; W B Isaacs; J W Simons; G L Semenza
Journal:  Cancer Res       Date:  1998-12-01       Impact factor: 12.701

Review 5.  The tumor microenvironment and its role in promoting tumor growth.

Authors:  T L Whiteside
Journal:  Oncogene       Date:  2008-10-06       Impact factor: 9.867

6.  The lysine demethylase, KDM4B, is a key molecule in androgen receptor signalling and turnover.

Authors:  Kelly Coffey; Lynsey Rogerson; Claudia Ryan-Munden; Dhuha Alkharaif; Jacqueline Stockley; Rakesh Heer; Kanagasabai Sahadevan; Daniel O'Neill; Dominic Jones; Steven Darby; Peter Staller; Alejandra Mantilla; Luke Gaughan; Craig N Robson
Journal:  Nucleic Acids Res       Date:  2013-02-21       Impact factor: 16.971

7.  The association between histone 3 lysine 27 trimethylation (H3K27me3) and prostate cancer: relationship with clinicopathological parameters.

Authors:  Marjolaine Ngollo; Andre Lebert; Aslihan Dagdemir; Gaelle Judes; Seher Karsli-Ceppioglu; Marine Daures; Jean-Louis Kemeny; Frederique Penault-Llorca; Jean-Paul Boiteux; Yves-Jean Bignon; Laurent Guy; Dominique Bernard-Gallon
Journal:  BMC Cancer       Date:  2014-12-23       Impact factor: 4.430

8.  HDAC8 Prevents Anthrax Lethal Toxin-induced Cell Cycle Arrest through Silencing PTEN in Human Monocytic THP-1 Cells.

Authors:  Soon-Duck Ha; Woohyun Cho; Sung Ouk Kim
Journal:  Toxins (Basel)       Date:  2017-05-16       Impact factor: 4.546

9.  A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response.

Authors:  Laurens Kruidenier; Chun-wa Chung; Zhongjun Cheng; John Liddle; KaHing Che; Gerard Joberty; Marcus Bantscheff; Chas Bountra; Angela Bridges; Hawa Diallo; Dirk Eberhard; Sue Hutchinson; Emma Jones; Roy Katso; Melanie Leveridge; Palwinder K Mander; Julie Mosley; Cesar Ramirez-Molina; Paul Rowland; Christopher J Schofield; Robert J Sheppard; Julia E Smith; Catherine Swales; Robert Tanner; Pamela Thomas; Anthony Tumber; Gerard Drewes; Udo Oppermann; Dinshaw J Patel; Kevin Lee; David M Wilson
Journal:  Nature       Date:  2012-08-16       Impact factor: 49.962

10.  Histone demethylase JMJD3 is required for osteoblast differentiation in mice.

Authors:  Feng Zhang; Longyong Xu; Longxia Xu; Qing Xu; Gerard Karsenty; Charlie Degui Chen
Journal:  Sci Rep       Date:  2015-08-25       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.